N,N-Dimethyl-tryptamin-N(b)-oxid | 948-19-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N,N-Dimethyl-tryptamin-N(b)-oxid
• 英文别名: Dimethyltryptamine-N-oxide；2-(1H-indol-3-yl)-N,N-dimethylethanamine oxide
• CAS: 948-19-6
• 化学式: C₁₂H₁₆N₂O
• 分子量: 204.272
• InChiKey: FSRSWKRQDYWUFG-UHFFFAOYSA-N

物化性质

• 熔点：
  47-49 °C
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  33.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N,N-二甲基色胺 在 双氧水 作用下， 生成 N,N-Dimethyl-tryptamin-N(b)-oxid
  参考文献：
  名称：

  Piptadenia Alkaloids. Indole Bases of P. peregrina (L.) Benth. and Related Species

  摘要：

  DOI：

  10.1021/ja01627a034

文献信息

• Nicotine free herbal composition for smoking de-addiction and treatment of side-effects and/or ailments from smoking
  申请人：Singh Gurseet

  公开号：US11013778B2

  公开（公告）日：2021-05-25

  The present disclosure provides nicotine free anti-smoking compositions comprising synergistic combination of herbal ingredients. In a preferred embodiment of the present disclosure, the anti-smoking composition can include combination of at least two herbs selected from the group consisting of Kapikachu, Ashwagandha, Tulsi, Haridra, Amla, Gokshura, Brahmi, Yashtimadhu, Sunthi, Lavang, Bala, Vidarikand, Jatanamsi, Shatavari, and Musli. In another preferred embodiment of the disclosure, the anti-smoking composition can further include one or more additional herbs selected from the group consisting of Guduchi, Draksha, Sirish, Arjuna, Mandukparni, Vasa, Karpoor, Kankol, Kantakari and Shigru. The formulation(s) in accordance with embodiments of the present disclosure not only provides anti-smoking effect but also treat side-effects and/or ailments arising from smoking.

  本公开提供了不含尼古丁的禁烟组合物，其中包含草药成分的协同组合。在本公开的一个优选实施方案中，禁烟组合物可以包括至少两种草药的组合，这些草药选自 Kapikachu、Ashwagandha、Tulsi、Haridra、Amla、Gokshura、Brahmi、Yashtimadhu、Sunthi、Lavang、Bala、Vidarikand、Jatanamsi、Shatavari 和 Musli 组成的组。在本公开的另一个优选实施方案中，禁烟组合物可以进一步包括一种或多种额外的草药，这些草药选自由 Guduchi、Draksha、Sirish、Arjuna、Mandukparni、Vasa、Karpoor、Kankol、Kantakari 和 Shigru 组成的组。根据本公开的实施方案配制的制剂不仅具有禁烟效果，还能治疗吸烟引起的副作用和/或疾病。
• Anti-Parkinson's disease pharmaceutical and method of use
  申请人：Manyam V. Bala

  公开号：US20050202111A1

  公开（公告）日：2005-09-15

  Employing a novel method of extracting Mucuna pruriens cotyledons, a composition for the treatment of Parkinson's disease has now been found which provides effective immediate relief of symptoms and also slows down the disease process. Because this novel composition can be given to patients by multiple routes of administration including injection, the Mucuna pruriens cotyledon extract of the present invention provides a distinct advantage over known Mucuna pruriens powder and extract preparations.

  采用新型方法提取 子叶 子叶的新方法，现已发现一种用于治疗帕金森病的组合物，它能立即有效地缓解症状，还能延缓疾病的进程。由于这种新型组合物可以通过多种给药途径（包括注射）给病人服用，因此 金丝桃 本发明的子叶提取物与已知的 粉末和提取物制剂相比，本发明的 粉和提取物制剂相比具有明显的优势。
• Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases
  申请人：Van Der Giessen Rob

  公开号：US20060165822A1

  公开（公告）日：2006-07-27

  The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases. Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.

  本发明提供的药物组合物包含 金丝桃 种子或一种或多种 种子成分、物质、馏分或混合物 种子成分、物质、馏分或混合物或从中获得的物质。此外，本发明还涉及使用 白桑子 种子粉末或一种或多种 成分、物质、馏分或混合物的用途。 成分、物质、馏分或混合物或从中获得的物质，用于制备预防、缓解或治疗神经系统疾病的药物组合物。此外，本发明还涉及使用 种子 种子用于制备神经保护或神经刺激的药物组合物，以及制备以下提取物的方法 的提取物的制备方法。 的提取物的制备方法，这些提取物可用于制备治疗神经系统疾病的药物组合物。最后，本发明涉及使用 种子 种子用于制备治疗帕金森病的药物组合物，以获得更广泛的左旋多巴治疗窗口，延迟联合治疗的需要，获得更早的左旋多巴疗效和更长的疗效持续时间，以及预防或减轻急性和慢性左旋多巴毒性。
• Tryptamine derivatives as novel non-nucleosidic inhibitors against hepatitis B virus
  作者：Shi-Jin Qu、Gui-Feng Wang、Wen-Hu Duan、Shan-Yan Yao、Jian-Ping Zuo、Chang-Heng Tan、Da-Yuan Zhu

  DOI：10.1016/j.bmc.2011.04.004

  日期：2011.5

  A series of tryptamine derivatives were synthesized and evaluated for their anti-hepatitis B virus (HBV) activity and cytotoxicity in the HepG2.2.15 cell line. The preliminary SAR was discussed. Compounds 2e and 4a showed potent antiviral activity (IC(50) = 0.4 and < 1 mu M, respectively) and low cytotoxicity (CC(50) = 40.6 and > 25 mu M, respectively). (C) 2011 Elsevier Ltd. All rights reserved.
• MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES
  申请人：Phytrix AG

  公开号：EP1567177B1

  公开（公告）日：2008-04-23